Skip to main content

Advertisement

Table 2 Frequency of clinical inactive disease and low disease activity parameters at cross-sectional visit of patients in MTX and biologic era cohorts

From: Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era

  MTX era (n = 239) Biologic era (n = 269) P
Oligoarthritis (n = 102) (n = 136)  
 Patients with physician global assessment = 0 34/100 (34.0) 85/134 (63.4) < 0.0001
 Patients with active joint count = 0 33/102 (32.4) 90/136 (66.2) < 0.0001
 Patients with parent global assessment = 0 37/96 (38.5) 61/114 (53.5) 0.0303
 Patients with parent pain assessment = 0 39/95 (41.1) 65/122 (53.3) 0.074
 Patients with ID by Wallace criteria 26/93 (28.0) 54/94 (57.4) < 0.0001
 Patients with ID by JADAS10 24/85 (28.2) 41/78 (52.6) 0.0015
 Patients with ID by cJADAS10 28/95 (29.5) 63/111 (56.8) < 0.0001
 Patients with LDA by JADAS10 29/85 (34.1) 43/78 (55.1) 0.0070
 Patients with LDA by cJADAS10 32/95 (33.7) 64/111 (57.7) 0.0010
Polyarthritis (n = 137) (n = 133)  
 Patients with physician global assessment = 0 25/132 (18.9) 76/133 (57.1) < 0.0001
 Patients with active joint count = 0 25/136 (18.4) 78/133 (58.6) < 0.0001
 Patients with parent global assessment = 0 33/127 (26.0) 53/113 (46.9) 0.0007
 Patients with parent pain assessment = 0 38/125 (30.4) 58/118 (49.2) 0.0028
 Patients with ID by Wallace criteria 19/129 (14.7) 48/98 (49.0) < 0.0001
 Patients with ID by JADAS10 19/115 (16.5) 34/84 (40.5) 0.0002
 Patients with ID by cJADAS10 21/122 (17.2) 54/112 (48.2) < 0.0001
 Patients with LDA by JADAS10 33/115 (28.7) 52/84 (61.9) < 0.0001
 Patients with LDA by cJADAS10 29/122 (23.8) 60/112 (53.6) < 0.0001
  1. Data are number positive/number with information available (percentage); reference [11]
  2. MTX methotrexate, ID inactive disease, LDA low disease activity, JADAS10 Juvenile Disease Activity Score 10, cJADAS Clinical Juvenile Disease Activity Score 10